Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback